CAMBRIDGE, MASSACHUSETTS — June 16, 2008. IntelligentMDx announced David Dolinger, Ph.D., Vice President, Research and Development. Dr. David Dolinger has over 18 years of industry experience in biotechnology and molecular diagnostics. His leadership and expertise will guide IntelligentMDx in expanding and manufacturing a broad menu of molecular tests.
Prior to joining IntelligentMDx Dr. Dolinger worked in the areas of drug discovery, pharmacogenomics, and diagnostics, as well as founded his own company. David was former Director of Research and Development for IQuum, Inc., a Senior Manager of Product Support for Bayer Diagnostics and Scientific Director with Visible Genetics, Inc. which developed the first FDA cleared sequencing based assay. David is considered a thought leader in molecular diagnostics and their regulation.
Dr. Dolinger received his doctorate in Microbiology and Immunology from Temple University Medical School and did his postdoctoral training at Princeton University.
Dr. Alice Jacobs, CEO of IntelligentMDx said, “David is an excellent addition to our team. His experience in molecular diagnostics will be of great advantage to our rapidly growing company.”
Dr. James Hully, Director of Research and principal inventor of key IntelligentMDx technologies shared similar sentiment, “I look forward to working closely with David to improve our testing capabilities. The company is currently in an exciting stage. I have confidence in David’s ability to guide our R&D efforts.”
Dr. Dolinger is charged with expanding the Research and Development team. His prior experience and expertise with the FDA approval process will be a great resource during IntelligentMDx’s rapid growth.